Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

ConclusionsWe found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews.
Source: Clinical and Translational Allergy - Category: Allergy & Immunology Source Type: research